Autoradiographic reevaluation of the binding properties of 125I-[Leu31,Pro34]peptide YY and 125I-peptide YY3-36 to neuropeptide Y receptor subtypes in rat forebrain.
125I-[Leu31,Pro34]peptide YY (PYY) and 125I-PYY3-36, initially described as selective neuropeptide Y Y1 and Y2 receptor ligands, respectively, were recently shown to label also Y4 and Y5 receptors. We used receptor autoradiography to assess whether these ligands can be reliably used to investigate the various neuropeptide Y receptors in rat forebrain. In most of the brain regions examined (in coronal sections at the level of dorsal hippocampus), specific 125I-[Leu31,Pro34]PYY binding was completely inhibited by 1 microM BIBP-3226, a selective Y1 receptor ligand, but unaffected by 10 nM rat pancreatic polypeptide, selectively inhibiting Y4 receptors, suggesting that Y4 receptors are present in negligible numbers compared with Y1 receptors in the areas examined. Significant numbers of BIBP-3226-insensitive 125I-[Leu31,Pro34]PYY binding sites were measured in the CA3 subfield of the hippocampus only, possibly representing Y5 receptors. 125I-PYY3-36 binding was unchanged by 1 microM BIBP-3226, whereas a population of 125I-PYY3-36 binding sites was sensitive to 100 nM [Leu31,Pro34]neuropeptide Y, likely representing Y5 receptors. The possibility of distinguishing between Y2 and Y5 receptors using 125I-PYY3-36 as radioligand was validated by their different regional distribution and their distinct changes 24 h after kainate seizures, i.e., binding to Y5 receptors was selectively decreased in the outer cortex, whereas binding to Y2 receptors was enhanced in the hippocampus. Thus, the use of selective unlabeled compounds is required for distinguishing the various receptor subtypes labeled by 125I-[Leu31,Pro34]PYY and 125I-PYY3-36 in rat brain tissue.
Gobbi
M
M
Laboratories of Receptor Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy.
Mennini
T
T
Vezzani
A
A
D000818:Animals; D001345:Autoradiography; D001923:Brain Chemistry / Q000502:physiology; D004827:Epilepsy / Q000139:chemically induced / Q000378:metabolism; D018690:Excitatory Amino Acid Agonists; D005768:Gastrointestinal Hormones / Q000378:metabolism / Q000494:pharmacology*; D007457:Iodine Radioisotopes; D007608:Kainic Acid; D008297:Male; D010446:Peptide Fragments; D019894:Peptide YY / Q000378:metabolism / Q000494:pharmacology*; D016548:Prosencephalon / Q000737:chemistry* / Q000378:metabolism*; D011485:Protein Binding / Q000502:physiology; D011869:Radioligand Assay; D051381:Rats; D017207:Rats, Sprague-Dawley; D017476:Receptors, Neuropeptide Y / Q000378:metabolism*
D018690:Excitatory Amino Acid Agonists; D005768:Gastrointestinal Hormones; D007457:Iodine Radioisotopes; D010446:Peptide Fragments; D017476:Receptors, Neuropeptide Y; C097212:neuropeptide Y-Y1 receptor; C095889:neuropeptide Y2 receptor; C100568:neuropeptide Y5 receptor; C106655:peptide YY, iodo-Leu(34)-Pro(34)-; D019894:Peptide YY; C061785:peptide YY (3-36); C109491:neuropeptide Y4 receptor; D007608:Kainic Acid